Progress and Controversies in Gynecologic Oncology Conference

Transcription

1 2013 This meeting is a prime Oncology activity. Progress and Controversies in Gynecologic Oncology Conference February 2013 Haliç Congress Center Istanbul, Turkey

2 Welcome On behalf of the Scientific Committee, we are pleased to invite you to the 2013 Progress and Controversies in Gynecologic Oncology Conference, to be held in Istanbul, Turkey, on February This meeting will serve as a valuable forum for the presentation and discussion of newly available data across various gynecologic malignancies including ovarian, cervical, and endometrial cancers. Participants will be provided with an update on practice-changing data in a practical and interactive format, fostering discussion and impacting clinical outcomes for patients. Who Should Attend The 2013 Progress and Controversies in Gynecology Oncology Conference is intended for gynecologists, oncologists, radiation therapists, surgeons, pathologists, and other practitioners including allied health professionals, involved in the management of gynecologic malignancies. Learning Objectives After successful completion of this educational activity, participants should be able to: * Develop a practical approach to cervical cancer staging and disease management * Discuss the role of radiotherapy and systemic therapies in the management of endometrial cancer * Derive the optimal surgical management of ovarian cancer based on disease stage and clinical presentation * Assess standard and emerging therapeutic options for ovarian cancer and discuss their impact on patient outcomes Continuing Education 2013 Progress and Controversies in Gynecologic Oncology Conference is accredited by the European Accreditation Council for Continuing Medical Education (EACCME) to provide the following CME activity for medical specialists. The EACCME is an institution of the European Union of Medical Specialists (UEMS), Progress and Controversies in Gynecologic Oncology Conference has been designated a maximum of 8 hours of European CME credits (ECMECs). The Congress operates an honour system implying that each medical specialist is expected to claim only those hours of credit that he/she actually spent at the Congress (with a maximum of 6 credits per day, 3 for a half day). Support Support for this educational activity is provided by F. Hoffmann-La Roche Ltd.

3 Venue Haliç Congress Center Sütlüce Mah. Eski Karaa ğaç Cad. Istanbul, Turkey Accommodation Figür Congress Organisation has been appointed as our official housing agency. To book your hotel accommodation, please visit our Website: or Registration Registration Fees Registration fees include VAT. *Supporting documentation of eligibility may be required. Registration Deadlines Early registration rate: 17 December 2012 (23.59 CET) Regular registration rate: 27 January 2013 (23.59 CET) Early Regular Late/Onsite Physician 375,- 475,- 575,- Nurse 225,- 300,- 350,- Fellow/Resident/Student* 225,- 300,- 350,- Industry/Society/Press 300,- 400,- 500,- To Register You may register online through 10 February 2013 at Registration confirmations will be issued upon successful completion of registration and reminders will be issued before the meeting. To preregister, registration and payment must be received no later than 17 December (early registration rate) or 1 February 2013 (regular registration rate). Please register onsite after 10 February. All payments must be made in Euros. Group Registrations Group registration will be accepted. For more information, please contact: registrations.gyn2013@primeoncology.org. Cancellation To receive a refund of registration fees, written notice of cancellation must be received at registrations.gyn2013@primeoncology.org. The following deadlines and cancellation fee schedule will apply: * Before 18 December 2012: 50,- administrative charge * From 18 December 2012: 60% cancellation fee applies on registration fee(s) * From 26 January 2013: 100% cancellation fee applies on registration fee(s) * Name changes from 26 January 2013: 15,- fee is charged per change Any registration fees remitted will be refunded after the Conference. Substitutions are accepted with written notification. No refunds will be made if notice is received after 26 January prime Oncology does not accept responsibility for reimbursement of travel, accommodation, or any other costs incurred by registrants in the rare event that this meeting should be canceled for any reason. Every effort will be made to give reasonable notice in the event of cancellation. The event agenda is subject to change without notice.

4 Scientific Committee Ali Ayhan, MD Baskent University Ankara, Turkey Andreas du Bois, MD, PhD Klinikum Essen Mitte Essen, Germany Nicoletta Colombo, MD University of Milan-Bicocca Milan, Italy Stanley B. Kaye, MD The Royal Marsden Hospital Sutton, United Kingdom Bradley J. Monk, MD, FACS, FACOG Creighton University School of Medicine at St Joseph s Hospital and Medical Center Phoenix, Arizona, United States Andrés Poveda, MD Fundacion Instituto Valenciano de Oncologia Valencia, Spain Eric Pujade-Lauraine, MD, PhD Centre Hospitalier Universitaire Hotel-Dieu Paris, France Ignace Vergote, MD, PhD University Hospital Gasthuisberg Leuven, Belgium

5 Faculty Giovanni Aletti, MD European Institute of Oncology Milan, Italy Christian Marth, MD, PhD Innsbruck University Hospital Innsbruck, Austria Frederic Amant, MD, PhD Catholic University Leuven, Belgium Mansoor R. Mirza, MD Rigshospitalet Copenhagen, Denmark Roberto Angioli, MD University of Rome Campus Biomedico Rome, Italy Jacobus Pfisterer, MD, PhD Cancer Center Kiel Kiel, Germany Paolo Casali, MD Istituto Nazionale Tumori Milan, Italy Isabelle Ray-Coquard, MD, PhD Centre Léon Bérard Lyon, France Antonio González Martín, MD M. D. Anderson Cancer Center Madrid, Spain Christine Haie-Meder, MD Institut Gustave Roussy Villejuif, France Nicholas Reed, MD Beatson Oncology Centre Gartnavel General Hospital Glasgow, United Kingdom Lukas Rob, MD, PhD Charles University Prague, Czech Republic Philipp Harter, MD Klinikum Essen Mitte Essen, Germany Michael Seckl, MD, PhD Imperial College London, United Kingdom Douglas Levine, MD, FACOG, FACS Memorial Sloan-Kettering Cancer Center New York, New York, United States Complete congress information and registration available at:

6 Agenda Friday, 15 February Welcome and introduction Ali Ayhan, MD Session I Cervical Cancer and Vaginal Cancer Interactive Clinical Case: Treatment of small cervical cancer: Perspectives on sparing fertility and conservative surgery Lukas Rob, MD, PhD Expert Opinion/Debate: Treatment for locally advanced early IIB cervical cancer: Neoadjuvant therapy vs radiotherapy Pro neoadjuvant therapy: Giovanni Aletti, MD Pro radiotherapy: Christine Haie-Meder, MD Update on systemic therapy for recurrent or metastatic cervical cancer Bradley J. Monk, MD, FACS, FACOG Updates in the treatment of vaginal cancer Roberto Angioli, MD Break Session II Endometrial Cancer and Beyond Insights into the management of gynecologic malignancies during pregnancy Frederic Amant, MD, PhD Expert Opinion/Debate: There are still indications for radiotherapy in endometrial cancer Pro: Nicholas Reed, MD Contra: Mansoor R. Mirza, MD Interactive Clinical Case: Leiomyosarcoma Paolo Casali, MD Update on advanced/recurrent uterine neoplasm management: Evaluating new agents Andrés Poveda, MD Concluding remarks: Day Adjourn

7 Agenda Saturday, 16 February Welcome and introduction Session III Ovarian Neoplasm I: First-Line Therapy Concepts in the biology of ovarian cancer: The impact of genetics on clinical practice Douglas Levine, MD, FACOG, FACS Role of radical surgery and neoadjuvant chemotherapy in advanced ovarian cancer: Report on the consensus paper of Leuven and Essen Ignace Vergote, MD, PhD Interactive Clinical Case: First-line therapy for advanced ovarian cancer Jacobus Pfisterer, MD, PhD Break Session IV Ovarian Neoplasm II: Emerging Novel Therapies Antiangiogenesis Eric Pujade-Lauraine, MD, PhD Beyond antiangiogenesis Stanley B. Kaye, MD Luncheon Symposium provided by F. Hoffmann-La Roche Ltd. Session V Ovarian Neoplasm III: Recurrence Surgery for recurrent ovarian cancer Philipp Harter, MD Interactive Clinical Case: Platinum-resistant disease Christian Marth, MD, PhD Interactive Clinical Case: Relapse at 6-12 months Antonio González Martín, MD Interactive Clinical Case: Platinum-sensitive disease Andreas du Bois, MD, PhD Rare tumor types in ovarian cancer 1) Trophoblastic disease Michael Seckl, MD, PhD 2) Germ cell tumors Isabelle Ray-Coquard, MD, PhD 3) Sex cord tumors Nicoletta Colombo, MD Concluding remarks: Day Adjourn

8 EU Office prime Oncology Scheveningseweg KW The Hague the Netherlands Register at: prime Oncology